ulcerative colitis and glp 1 GLP-1 medications are a major focus for scientists right now., Here’s what’s happening: between 2024 and 2025, at least six studies have been published in respected journals GLUCAGON-LIKE 1 RECEPTOR AGONIST USE

This genetic insight helps PlexusDx clinicians predict optimal medication selection and dosing strategy for your individual biology

It attaches once per NDA for the first Paragraph IV challenge

Finally, remember that volatility and hit frequency are not value judgments but styles

Both drugs have been on the FDAs drug shortage list since 2022

Additionally, signals from the brain, especially via the sympathetic and parasympathetic nervous systems and the ENS, can trigger intestinal inflammation and increased barrier permeability following CNS injury (428)

van den Heuvel JM, Farzan N, van Hoek M, Maitland-van der Zee A-H, Ahmadizar F